Clinical Trial Update: Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). [Phase 3]

View source ↗

Summary

Phase 3 extension study to evaluate long-term safety of ianalumab in systemic lupus erythematosus; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: RECRUITING